June 26, 2023—Qiagen announced that its variant interpretation and reporting software, Qiagen Clinical Insight (QCI) Interpret, was chosen by the Danish National Genome Center to provide interpretation of oncology results generated from whole genome sequencing data. The initiative is part of a larger personalized medicine strategy that aims to provide WGS as the standard of care for relevant patient groups throughout Denmark.
“Denmark is taking a visionary approach to aggregating genomic data and combining it with clinical information on cancer patients to develop enhanced population-specific knowledge and reference sets for the country’s residents,” Jonathan Sheldon, EVP and head of Qiagen Digital Insights, said in a press statement. “This will serve as a foundation for effective precision medicine capabilities for years to come. This partnership also demonstrates Qiagen’s ability to support national precision medicine programs in terms of infrastructure and technology support.”
QCI Interpret allows authorized staff from laboratories across the country to interpret whole genome sequencing data while meeting Denmark’s data privacy and security requirements, the company says, for all data to be processed and stored within the country and accessed only from within the National Genome Center infrastructure.